Eniluracil Hand Foot Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00827580|
Recruitment Status : Completed
First Posted : January 23, 2009
Last Update Posted : August 28, 2009
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Colon Cancer||Drug: Eniluracil Drug: Capecitabine||Phase 1|
- To estimate the frequency of HFS following treatment with capecitabine as modulated by the unilateral local application of eniluracil containing ointment.
- To assess any eniluracil dose response relationship in prevention of HFS.
- To evaluate any potential toxicity of eniluracil ointment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)|
|Study Start Date :||January 2009|
- the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00827580
|United States, West Virginia|
|Clinical Trials Research Unit, West Virginia University|
|Morgantown, West Virginia, United States, 226506|
|Principal Investigator:||William P. Petros, Pharm D||West Virginia University|